Clinical Trials and Research

AbstractBackground: Sickle cell disease is the most common genetic disorder in the world. It is a real public health problem in sub-Saharan Africa. Early screening…

AbstractAcute chest syndrome (ACS) is a common pulmonary complication in children with sickle cell disease, defined by a new pulmonary infiltrate on imaging…

Agios Pharmaceuticals will present Phase 3 trial results for mitapivat in sickle cell disease at EHA 2026.Quiver AI SummaryAgios Pharmaceuticals announced that…

Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults…

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through…

ABSTRACTErythrocytaphoresis or RBC exchange (RBCX) is a key intervention in the management of sickle cell anemia for both chronic prophylaxis and emergent clinical…

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia, recurrent vaso-occlusive crises, progressive organ damage, and…

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering…

Sickle cell disease (SCD) is one of the most prevalent autosomal recessive conditions worldwide, affecting more than 600,000 newborns annually. Despite advances in…

HLA-matched sibling donor (MSD) hematopoietic cell transplantation (HCT) done prior to adolescence demonstrated promising safety and efficacy outcomes among…